ARCHIVES

Dendreon Claims “Clear Hit” On Provenge, But Skeptics Await Data Presentation

This article is from The Cancer Letter archive.

Vol. 35 No. 15 | April 17, 2009

Download PDF Visit The Full Archive

Related Articles

NIH Director Healy Resigned, To Return To Cleveland In June’ Kessler To Remain

March 5, 1993

FDA News: FDA Approves Reagent System for Graft-Versus-Host Disease

January 24, 2014

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

June 3, 2005

Phase III Avastin Trial Fails Primary Endpoints

February 28, 2014

Bass & Howes Bought By DDB Seattle

March 22, 2002

Pacific Yew Act Would Result In Duplications, Delays In Taxol Production, Witnesses Say

March 13, 1992